Breaking News

Dendreon Gains Approval for Atlanta Manufacturing Facility

To manufacture cancer treatment Provenge

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Dendreon Corp. received approval from the FDA for its cancer immunotherapy manufacturing facility in Atlanta, GA for the production of Provenge (sipuleucel-T), a treatment for metastatic castrate resistant (hormone refractory) prostate cancer. The Atlanta facility includes 36 workstations. The company plans to bring these new workstations online in a staged approach. Along with NJ and CA facilities, Dendreon now has three facilities available to manufacture Provenge....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters